メインコンテンツにスキップ

Japanese Regulatory Agency Licenses Certara’s Phoenix and Simcyp Software

Pharmaceuticals and Medical Devices Agency (PMDA) is equipping its pharmacometrics team with Certara’s biosimulation software PRINCETON, NJ – Feb. 26, 2015 – Certara®, the global biosimulation technology-enabled drug development and drug safety consulting company, today announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) is equipping its pharmacometrics team with Certara’s Phoenix® biosimulation solutions … Continued

Phoenix WinNonlin Validation Suite: Decrease the Time and Cost of Your Validation

Do you or your company spend weeks or months manually performing the necessary steps for software validation? In this webinar, the Certara team discussed the requirements for computer system validation, how it’s performed, and how Certara’s validation products can significantly reduce the time, resources, and cost of the on-site validation of your Phoenix WinNonlin computer … Continued

Certara Donates Software to University of Maryland to Develop New Approaches to Drug Development

Gift of Phoenix® software licenses, workshop assistance, and training renews the strong partnership established between the two organizations in 2012 PRINCETON, NJ – Feb. 19, 2015 – Certara®, the global biosimulation technology-enabled drug development and drug safety consulting company, today announced that it has donated Phoenix software and licenses to the University of Maryland School … Continued

Certara Reinforces D360’s Position as Dominant Big Data Platform for the Biopharmaceutical Industry

D360 version 8.0 supports connections to broader and more diverse data sets, increases collaboration across silos, and delivers faster time to insight for scientific decision making PRINCETON, NJ – Feb. 17, 2015 – Certara®, the global biosimulation technology-enabled drug development and drug safety consulting company, today announced that it will be launching version 8.0 of … Continued

第2期ヒトアフリカトリパノソーマ症の化学療法:非経口ジアミジンDB829と当剤の経口のプロドラッグであるDB868とのベルベットモンキーにおける比較

Human African trypanosomiasis (HAT, sleeping sickness) ranks among the most neglected tropical diseases based on limited availability of drugs that are safe and efficacious, particularly against the second stage (central nervous system [CNS]) of infection. In response to this largely unmet need for new treatments, the Consortium for Parasitic Drug Development developed novel parenteral diamidines … Continued

Certara Staff to Demonstrate Drug Development Solutions at Scientific Webinar Series

Topics to be presented will include PBPK modeling and simulation, population modeling of e-cigarettes, and artificial intelligence technology for clinical trial transparency. PRINCETON, NJ – Feb. 6, 2015 – Certara®, the leading global technology-enabled drug development and drug safety consultancy, today announced that senior staff members from Certara will demonstrate their approaches to some of … Continued

Calculating the Elimination Rate Constant

The elimination rate constant is the rate at which drug is cleared from the body assuming first-order elimination. Various abbreviations are used to represent the elimination rate constant including ke, kel, λ, and λz. The calculation of the elimination rate constant can be done using pharmacokinetic parameters or it can be done directly from a … Continued

Population Pharmacokinetics of Ceftolozane/Tazobactam in Healthy Volunteers, Subjects with Varying Degrees of Renal Function and Patients with Bacterial Infections

Ceftolozane/tazobactam is a novel antipseudomonal cephalosporin and a β-lactamase inhibitor in clinical development for treatment of complicated urinary tract (cUTI) and intra-abdominal (cIAI) infections and nosocomial pneumonia. The population pharmacokinetics of ceftolozane/tazobactam were characterized in healthy volunteers, subjects with varying degrees of renal function, and patients with cIAI or cUTI. Serum concentration data from 376 … Continued

1 of 1
Powered by Translations.com GlobalLink OneLink Software